RxDoctor Payments Data

Ronald Lewis, MD

Internal Medicine · Lake Charles, LANPI 1326014523

Payments from drug & device makers

$7,115in general payments, 2019–2025

Across 438 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Amgen$816
  • AbbVie$651
  • Novo Nordisk$600
  • AstraZeneca$494
  • Boehringer Ingelheim$364
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,089100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,115 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$211,502
Medicare patients
422
Services billed
28,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide98$114,800
OzempicSemaglutide74$100,295
JardianceEmpagliflozin83$68,819
XareltoRivaroxaban68$63,218
EliquisApixaban62$60,278
TrulicityDulaglutide36$55,727
FarxigaDapagliflozin Propanediol35$26,175
Alosetron Hcl12$17,000
Repatha SureclickEvolocumab23$14,237
MyrbetriqMirabegron25$11,996
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$9,624
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl61$7,211
GemtesaVibegron11$6,924
Buprenorphine Hcl155$6,091
PremarinEstrogens, Conjugated11$5,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,048$170,527134 claims
Novo NordiskOzempic$600$100,29574 claims
Boehringer IngelheimJardiance$364$68,81983 claims
PfizerEliquis, Premarin$259$66,21673 claims
Johnson & JohnsonXarelto$135$63,21868 claims
AstraZenecaFarxiga$494$26,17535 claims
Astellas Pharma US IncMyrbetriq$184$11,99625 claims
GSKTrelegy Ellipta$154$9,62417 claims
Sumitomo Pharma America, Inc.Gemtesa$56$6,92411 claims
MerckJanumet Xr$272$5,70813 claims
Esperion Therapeutics, Inc.Nexletol$127$5,16113 claims
AbbVieSynthroid$651$1,55442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →